Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus

Abstract

We carried out a retrospective analysis of 40 Japanese patients with type2 diabetes mellitus who received sitagliptin. Glycated hemoglobin (HbA1c) and fasting plasma glucose were significantly decreased from 7.53±0.65% and 155.2±29.4mg/dL at baseline to 6.80±0.60% (P<0.01) and 131.2±22.3mg/dL (P<0.01) at week20, respectively. β-Cell function was evaluated by the secretory units of islets in transplantation (SUIT) index, which was significantly increased from 28.5±14.0 at baseline to 38.6±17.0 at week20 (P<0.01). Multivariate analysis was carried out between ΔHbA1c and several parameters (age, the duration of diabetes, body mass index, triglyceride [TG], C-peptide [CPR], ΔCPR, HbA1c [baseline] and ΔSUIT), which showed HbA1c (baseline; β=0.580, P<0.001) and ΔSUIT (β=0.308, P<0.05) as significant independent determinants of ΔHbA1c. These two variables explained 53% of the variance in HbA1c response. These results suggest that SUIT index can be a clinical marker for the efficacy of sitagliptin in treatment of diabetes mellitus. © 2011 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd.